2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
3
Melanoma
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Anus Neoplasms
1
Interventions
Radiotherapy
10
Cisplatin
9
pembrolizumab
6
Surveys and Questionnaires
6
Methods
6
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
5
fludarabine
4
Papillomavirus Vaccines
4
Early Intervention, Educational
4
Cyclophosphamide
4
Brachytherapy
4
durvalumab
3
aldesleukin
3
Vaccines, Synthetic
3
Vaccines
3
Sentinel Lymph Node Biopsy
3
Radiosurgery
3
Radiation
3
Platinum
3
Palliative Care
3
Paclitaxel
3
Nivolumab
3
Indocyanine Green
3
Gemcitabine
3
Drug Therapy
3
Carboplatin
3
Bleomycin
3
Biopsy
3
1,2-diaminocyclohexaneplatinum II citrate
3
tremelimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vulvar Neoplasms
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled